TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase Four Study of Intravenous Parecoxib on Post-craniotomy Pain
Brief Summary: Aim of this trial:

To investigate whether post-craniotomy analgesia with (i) intravenous (IV) parecoxib plus intravenous paracetamol is superior to (ii) intravenous paracetamol alone.

Study Hypothesis:

Post-operative analgesia with intravenous parecoxib in combination with intravenous paracetamol will be superior to intravenous paracetamol alone.


Options:
A: Arm Label: Group H (Hyaluronidase added to local anaesthetics); Type: ACTIVE_COMPARATOR; Interventions: Drug: Hyaluronidase, Drug: Lidocaine, Drug: Bupivacaine | Arm Label: Group A (local anaesthetics alone); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lidocaine, Drug: Bupivacaine | Intervention Type: DRUG; Name: Hyaluronidase; Assigned to Arm(s): Group H (Hyaluronidase added to local anaesthetics) | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group A (local anaesthetics alone), Group H (Hyaluronidase added to local anaesthetics) | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Group A (local anaesthetics alone), Group H (Hyaluronidase added to local anaesthetics)
B: Arm Label: IV Caldolor (ibuprofen); Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Caldolor | Arm Label: standard treatment group; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Intervention Type: DRUG; Name: IV Caldolor; Assigned to Arm(s): IV Caldolor (ibuprofen) | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): standard treatment group
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous Parecoxib ('Dynastat' Pfizer) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous Parecoxib ('Dynastat' Pfizer) | Intervention Type: DRUG; Name: Intravenous Parecoxib ('Dynastat' Pfizer); Assigned to Arm(s): 1, 2
D: Arm Label: Morphine 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Morphine 0.5; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Dexketoprofen & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexketoprofen, Drug: Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine 0.5, Morphine 1 mg | Intervention Type: DRUG; Name: Dexketoprofen; Assigned to Arm(s): Dexketoprofen & Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dexketoprofen & Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung.

Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.


Options:
A: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
B: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Arm Label: 2; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Intervention Type: DRUG; Name: rhDNAse; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1, 2
D: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung.

Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
C: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
D: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung.

Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung.

Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.


Options:
A: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704
Brief Summary: Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The objective of this extension study is to assess the long-term safety and efficacy of alglucosidase alfa treatment in patients with Late-Onset Pompe Disease who were previously treated under the placebo-controlled, double-blind study AGLU02704 (NCT00158600).


Options:
A: Arm Label: Albuterol; Type: EXPERIMENTAL; Interventions: Drug: Albuterol | Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Albuterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator
B: Arm Label: avalglucosidase alfa (GZ402666); Type: EXPERIMENTAL; Interventions: Drug: Avalglucosidase alfa (GZ402666) | Arm Label: alglucosidase alfa (GZ419829); Type: ACTIVE_COMPARATOR; Interventions: Drug: Alglucosidase alfa (GZ419829) | Intervention Type: DRUG; Name: Avalglucosidase alfa (GZ402666); Assigned to Arm(s): avalglucosidase alfa (GZ402666) | Intervention Type: DRUG; Name: Alglucosidase alfa (GZ419829); Assigned to Arm(s): alglucosidase alfa (GZ419829)
C: Arm Label: Cipaglucosidase Alfa/Miglustat; Type: EXPERIMENTAL; Interventions: Biological: Cipaglucosidase Alfa, Drug: Miglustat | Arm Label: Alglucosidase Alfa/Placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: Alglucosidase Alfa, Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Cipaglucosidase Alfa; Assigned to Arm(s): Cipaglucosidase Alfa/Miglustat | Intervention Type: DRUG; Name: Miglustat; Assigned to Arm(s): Cipaglucosidase Alfa/Miglustat | Intervention Type: BIOLOGICAL; Name: Alglucosidase Alfa; Assigned to Arm(s): Alglucosidase Alfa/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alglucosidase Alfa/Placebo
D: Arm Label: Alglucosidase Alfa/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): Alglucosidase Alfa/Alglucosidase Alfa, Placebo/Alglucosidase Alfa

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.
Brief Summary: Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial.

The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared.


Options:
A: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A
C: Arm Label: Risperidone; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.
Brief Summary: Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial.

The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared.


Options:
A: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: ALKS 9072; Type: EXPERIMENTAL; Interventions: Drug: ALKS 9072 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ALKS 9072; Assigned to Arm(s): ALKS 9072 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.
Brief Summary: Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial.

The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared.


Options:
A: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
B: Arm Label: Intramuscular ziprasidone; Type: EXPERIMENTAL; Interventions: Drug: Intramuscular ziprasidone mesylate | Arm Label: Intramuscular haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intramuscular haloperidol | Intervention Type: DRUG; Name: Intramuscular ziprasidone mesylate; Assigned to Arm(s): Intramuscular ziprasidone | Intervention Type: DRUG; Name: Intramuscular haloperidol; Assigned to Arm(s): Intramuscular haloperidol
C: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A
D: Arm Label: clozapine; Type: EXPERIMENTAL; Interventions: Drug: Clozapine | Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Arm Label: Haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Clozapine; Assigned to Arm(s): clozapine | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Haloperidol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of Tapentadol (CG5503) extended release (ER) (base) compared to placebo in patients with moderate to severe pain from diabetic peripheral neuropathy.


Options:
A: Arm Label: Matching Placebo (twice daily); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo (twice daily) | Arm Label: Tapentadol ER (100 to 250 mg twice daily); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (100 to 250 mg twice daily) | Arm Label: Oxycodone CR (20 to 50 mg twice daily); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR (20 to 50 mg twice daily) | Intervention Type: DRUG; Name: Tapentadol ER (100 to 250 mg twice daily); Assigned to Arm(s): Tapentadol ER (100 to 250 mg twice daily) | Intervention Type: DRUG; Name: Matching Placebo (twice daily); Assigned to Arm(s): Matching Placebo (twice daily) | Intervention Type: DRUG; Name: Oxycodone CR (20 to 50 mg twice daily); Assigned to Arm(s): Oxycodone CR (20 to 50 mg twice daily)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: CG5503; Type: EXPERIMENTAL; Interventions: Drug: CG5503 | Intervention Type: DRUG; Name: CG5503; Assigned to Arm(s): CG5503 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tapentadol Prolonged Release; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol Prolonged Release | Intervention Type: DRUG; Name: Tapentadol Prolonged Release; Assigned to Arm(s): Tapentadol Prolonged Release
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: tapentadol (CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: tapentadol (CG5503); Assigned to Arm(s): 001

Answer: B